Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action | Zendy

Wenyan Cai | Zendy; Jianbo Dong | Zendy; Sachith Gallolu Kankanamalage | Zendy; Allison Titong | Zendy; Jiadong Shi | Zendy; Zhejun Jia | Zendy; Bo Wang | Zendy; Cai Huang | Zendy; Jing Zhang | Zendy; Jun Lin | Zendy; Steven Z. Kan | Zendy; Shuhua Han | Zendy; Joe Zhou | Zendy; Yue Liu | Zendy

Open Access

Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action

Author(s) -

Wenyan Cai,

Jianbo Dong,

Sachith Gallolu Kankanamalage,

Allison Titong,

Jiadong Shi,

Zhejun Jia,

Bo Wang,

Cai Huang,

Jing Zhang,

Jun Lin,

Steven Z. Kan,

Shuhua Han,

Joe Zhou,

Yue Liu

Publication year - 2021

Publication title -

antibody therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.579

H-Index - 5

ISSN - 2516-4236

DOI - 10.1093/abt/tbab024

Subject(s) - cd20 , rituximab , cd3 , antibody , cancer research , monoclonal antibody , cytokine release syndrome , antigen , antibody dependent cell mediated cytotoxicity , medicine , t cell , immunology , immune system , cd8 , chimeric antigen receptor

Bispecific T cell engaging antibodies (TEAs) with one arm targeting a cancer antigen and another arm binding to CD3 have demonstrated impressive efficacy in multiple clinical studies. However, establishing a safety/efficacy balance remains challenging. For instance, some TEAs have severe safety issues. Additionally, not all patients or all cancer cells of one patient respond equally to TEAs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research